Elranatamab Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma

Pfizer has reported that elranatamab, marketed as Elrexfio, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients with relapsed or refractory multiple myeloma. The findings come from an interim analysis of the Phase 3 MagnetisMM-5 clinical trial.

The study focused on patients who are double-class exposed, meaning they have previously received treatments from two different classes of therapy. According to Pfizer, the drug met its primary endpoint, with the results exceeding the trial’s interim target analysis hazard ratio for efficacy.

Trial Results and Comparison

In the MagnetisMM-5 trial, elranatamab was administered as a monotherapy. It was compared against a standard-of-care regimen consisting of daratumumab, pomalidomide, and dexamethasone.

The interim analysis indicated that a majority of patients remained progression-exempt at the time of the analysis. Pfizer stated that the safety profile of the drug remained consistent with the known profile of Elrexfio, with no new safety signals identified during this phase of the study.

Clinical Context and Patient Impact

Multiple myeloma is a cancer of plasma cells that often requires multiple lines of therapy as the disease relapses or becomes refractory to initial treatments. Elranatamab is a BCMA-CD3-targeted bispecific antibody designed to engage T cells to target and kill malignant plasma cells.

Previously, the U.S. Food and Drug Administration granted accelerated approval to elranatamab-bcmm on August 14, 2023. At that time, the approval was limited to adults with relapsed or refractory multiple myeloma who had previously received at least four lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

The results from the MagnetisMM-5 trial suggest that the therapy may be effective in an earlier line of treatment than the current approved use. By demonstrating efficacy in patients who have received fewer prior therapies, the drug could potentially move earlier into the treatment sequence for patients who have failed their first line of therapy.

Future Regulatory Directions

Following the success of the Phase 3 trial, Pfizer indicated it will seek approval to use Elrexfio in an earlier setting for relapsed or refractory multiple myeloma. The company aims to position the drug as a potential second-line option, reducing the number of subsequent regimens patients must cycle through before exhausting available treatments.

The transition to earlier-line use depends on the final analysis of the trial data and subsequent regulatory review by health authorities to ensure that the benefit-risk profile remains favorable for patients with less extensive prior treatment history.